泰克司他单抗治疗复发难治性多发性骨髓瘤：法国早期介入计划的一项多机构真实世界研究。

IF 8.2 1区医学 Q1 HEMATOLOGY

Haematologica Pub Date : 2024-11-21 DOI:10.3324/haematol.2024.286118

Aurore Perrot, Cyrille Hulin, Ariane Boumendil, Hamza Manjra, Antoine Leveque, Carolyne Croizier, Arthur Dony, Mohamad Mohty, Murielle Roussel, Salomon Manier, Frédérique Orsini-Piocelle, Loic Bauschert, Arthur Bobin, Laurent Frenzel, Laure Vincent, Claire Breal, Jean Richard Eveillard, Thomas Gerome, Mourad Tiab, Emilie Chalayer, Rakiba Belkhir, Clara Mariette, Perrine Moyer, Thomas Chalopin, Brieuc Cherel, Lydia Montes, Arthur Coste, Reza Tabrizi, Lionel Karlin, Daniella Robu, Amandine Huguet, Stéphanie Harel, Philippe Moreau

引用次数: 0

摘要

不详。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program.

Not available.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.